Compare TSBK & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TSBK | ABEO |
|---|---|---|
| Founded | 1915 | 1974 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 357.0M | 399.5M |
| IPO Year | 1997 | 2005 |
| Metric | TSBK | ABEO |
|---|---|---|
| Price | $43.73 | $5.05 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $18.88 |
| AVG Volume (30 Days) | 19.7K | ★ 1.3M |
| Earning Date | 10-29-2026 | 11-11-2026 |
| Dividend Yield | ★ 2.69% | N/A |
| EPS Growth | N/A | ★ 165.16 |
| EPS | ★ 2.92 | N/A |
| Revenue | N/A | ★ $2,998,000.00 |
| Revenue This Year | N/A | $804.33 |
| Revenue Next Year | N/A | $119.68 |
| P/E Ratio | $15.36 | ★ N/A |
| Revenue Growth | N/A | ★ 258.18 |
| 52 Week Low | $30.96 | $4.00 |
| 52 Week High | $49.38 | $7.65 |
| Indicator | TSBK | ABEO |
|---|---|---|
| Relative Strength Index (RSI) | 37.55 | 35.55 |
| Support Level | $42.88 | $4.94 |
| Resistance Level | $45.37 | $5.46 |
| Average True Range (ATR) | 0.86 | 0.21 |
| MACD | -0.21 | -0.01 |
| Stochastic Oscillator | 19.32 | 11.39 |
Timberland Bancorp Inc is a bank holding company for Timberland Bank. The bank offers banking services including personal checking and savings accounts, debit cards, health savings accounts, online and mobile banking, online bill pay, 24-hour phone banking, and Zelle. Business services include business checking accounts, online banking, remote deposit, ACH transactions, Autobooks, and insured cash sweep services. The bank also provides lending services such as personal credit cards, home loans, home equity borrowing, construction loans, and SBA loans. In addition, it offers loans to real estate, including residential and commercial real estate, multi-family construction loans, one- to four-family residential loans, multi-family loans, commercial real estate loans, and land loans.
Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.